Answers are grounded in this paper and cite their sources.
Use of PZQ will increase in the foreseeable future, whether given alone or coadministered with other anthelminthics in integrated control programmes. PZQ resistance remains a threat and its prevention requires adequate monitoring of current mass drug administration programmes and development of new schistosomicides.
No takes yet. Share an insight, caveat, or question.
Doenhoff et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: